Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Diabetes

  Free Subscription


Articles published in J Hypertens

Retrieve available abstracts of 107 articles:
HTML format
Text format



Single Articles


    May 2018
  1. VIRDIS A, Masi S, Grassi G
    Albuminuria and diabetes: a question of eye and skin points of view.
    J Hypertens. 2018;36:1036-1037.
    PubMed     Text format    


    April 2018
  2. VIAZZI F, Ceriello A, Fioretto P, Giorda C, et al
    Changes in albuminuria and renal outcome in patients with type 2 diabetes and hypertension: a real-life observational study.
    J Hypertens. 2018 Apr 19. doi: 10.1097/HJH.0000000000001749.
    PubMed     Text format     Abstract available


  3. KOTSIS V, Tsioufis K, Antza C, Seravalle G, et al
    Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part B: obesity-induced cardiovascular disease
    J Hypertens. 2018 Apr 12. doi: 10.1097/HJH.0000000000001731.
    PubMed     Text format     Abstract available


  4. KOTSIS V, Jordan J, Micic D, Finer N, et al
    Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hyperten
    J Hypertens. 2018 Apr 9. doi: 10.1097/HJH.0000000000001730.
    PubMed     Text format     Abstract available


    March 2018
  5. BOMBELLI M, Quarti-Trevano F, Tadic M, Facchetti R, et al
    Uric acid and risk of new-onset metabolic syndrome, impaired fasting glucose and diabetes mellitus in a general Italian population: data from the Pressioni Arteriose Monitorate E Loro Associazioni study.
    J Hypertens. 2018 Mar 14. doi: 10.1097/HJH.0000000000001721.
    PubMed     Text format     Abstract available


    January 2018
  6. EGUCHI K, Hoshide S, Kario K
    Target home morning SBP be below 125 mmHg in type 2 diabetes patients.
    J Hypertens. 2018 Jan 23. doi: 10.1097/HJH.0000000000001683.
    PubMed     Text format     Abstract available


  7. YANNOUTSOS A, Bahous SA, Safar ME, Blacher J, et al
    Clinical relevance of aortic stiffness in end-stage renal disease and diabetes: implication for hypertension management.
    J Hypertens. 2018 Jan 2. doi: 10.1097/HJH.0000000000001665.
    PubMed     Text format     Abstract available


  8. ZHANG Y, Jiang X, Bo J, Yin L, et al
    Risk of stroke and coronary heart disease among various levels of blood pressure in diabetic and nondiabetic Chinese patients.
    J Hypertens. 2018;36:93-100.
    PubMed     Text format     Abstract available


  9. AHMAD A, Oparil S
    What is the most appropriate target SBP in persons with hypertension and diabetes mellitus?
    J Hypertens. 2018;36:37-40.
    PubMed     Text format    


    December 2017
  10. USHIGOME E, Matsumoto S, Oyabu C, Kitagawa N, et al
    Prognostic significance of day-by-day variability of home blood pressure on progression to macroalbuminuria in patients with diabetes.
    J Hypertens. 2017 Dec 27. doi: 10.1097/HJH.0000000000001657.
    PubMed     Text format     Abstract available


  11. BEUSCHLEIN F, Reincke M, Arlt W
    The impact of Connshing's syndrome - mild cortisol excess in primary aldosteronism drives diabetes risk.
    J Hypertens. 2017;35:2548.
    PubMed     Text format    


    September 2017
  12. ZHOU TL, Kroon AA, Reesink KD, Schram MT, et al
    Blood pressure variability in individuals with and without (pre)diabetes: The Maastricht Study.
    J Hypertens. 2017 Sep 6. doi: 10.1097/HJH.0000000000001543.
    PubMed     Text format     Abstract available


    August 2017
  13. O HARTAIGH B, Szymonifka J, Okin PM
    Achieving target SBP for lowering the risk of major adverse cardiovascular events in persons with diabetes mellitus.
    J Hypertens. 2017 Aug 21. doi: 10.1097/HJH.0000000000001515.
    PubMed     Text format     Abstract available


  14. GOMADAM P, Shah A, Qureshi W, Yeboah PN, et al
    Blood pressure indices and cardiovascular disease mortality in persons with or without diabetes mellitus.
    J Hypertens. 2017 Aug 10. doi: 10.1097/HJH.0000000000001509.
    PubMed     Text format     Abstract available


  15. WU VC, Chueh SJ, Chen L, Chang CH, et al
    Risk of new-onset diabetes mellitus in primary aldosteronism: a population study over 5 years.
    J Hypertens. 2017;35:1698-1708.
    PubMed     Text format     Abstract available


  16. HITOMI H, Nishiyama A
    How should we treat patients with primary aldosteronism to prevent new-onset diabetes mellitus?
    J Hypertens. 2017;35:1575-1576.
    PubMed     Text format    


    June 2017
  17. FUNCK KL, Laugesen E, Ovrehus K, Jensen JM, et al
    Increased high-risk coronary plaque burden is associated with arterial stiffness in patients with type 2 diabetes without clinical signs of coronary artery disease: a computed tomography angiography study.
    J Hypertens. 2017;35:1235-1243.
    PubMed     Text format     Abstract available


    May 2017
  18. VEUGEN MG, Henry RM, van Sloten TT, Hermeling E, et al
    The systolic-diastolic difference in carotid stiffness is increased in type 2 diabetes: The Maastricht Study.
    J Hypertens. 2017;35:1052-1060.
    PubMed     Text format     Abstract available


    March 2017
  19. BAHADORAN Z, Mirmiran P, Momenan AA, Azizi F, et al
    Allium vegetable intakes and the incidence of cardiovascular disease, hypertension, chronic kidney disease, and type 2 diabetes in adults: a longitudinal follow-up study.
    J Hypertens. 2017 Mar 17. doi: 10.1097/HJH.0000000000001356.
    PubMed     Text format     Abstract available


    February 2017
  20. ZANCHETTI A
    Problems of antihypertensive management: diabetes mellitus, ethnic differences, organ damage and resistance to treatment.
    J Hypertens. 2017 Feb 27. doi: 10.1097/HJH.0000000000001334.
    PubMed     Text format    


  21. ATKINS ER, Hirakawa Y, Salam A, Woodward M, et al
    Side effects and tolerability of combination blood pressure lowering according to blood pressure levels: an analysis of the perindopril protection against recurrent stroke study and action in diabetes and vascular disease: preterax and diamicron-MR co
    J Hypertens. 2017 Feb 6. doi: 10.1097/HJH.0000000000001287.
    PubMed     Text format     Abstract available


    January 2017
  22. THOMOPOULOS C, Parati G, Zanchetti A
    Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials.
    J Hypertens. 2017 Jan 30. doi: 10.1097/HJH.0000000000001276.
    PubMed     Text format     Abstract available


  23. KUMARATHURAI P, Anholm C, Fabricius-Bjerre A, Nielsen OW, et al
    Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study.
    J Hypertens. 2017 Jan 27. doi: 10.1097/HJH.0000000000001275.
    PubMed     Text format     Abstract available


  24. DASGUPTA K, Rosenberg E, Joseph L, Trudeau L, et al
    Carotid femoral pulse wave velocity in type 2 diabetes and hypertension: capturing arterial health effects of step counts.
    J Hypertens. 2017 Jan 27. doi: 10.1097/HJH.0000000000001277.
    PubMed     Text format     Abstract available


  25. HAMET P, Haloui M, Harvey F, Marois-Blanchet FC, et al
    PROX1 gene CC genotype as a major determinant of early onset of type 2 diabetes in slavic study participants from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation study.
    J Hypertens. 2017 Jan 5. doi: 10.1097/HJH.0000000000001241.
    PubMed     Text format     Abstract available


  26. OH JY, Allison MA, Barrett-Connor E
    Different impacts of hypertension and diabetes mellitus on all-cause and cardiovascular mortality in community-dwelling older adults: the Rancho Bernardo Study.
    J Hypertens. 2017;35:55-62.
    PubMed     Text format     Abstract available


    November 2016
  27. BRUNSTROM M, Eliasson M, Nilsson PM, Carlberg B, et al
    Blood pressure treatment levels and choice of antihypertensive agent in people with diabetes mellitus: an overview of systematic reviews.
    J Hypertens. 2016.
    PubMed     Text format     Abstract available


    September 2016
  28. BRUNO R, Vitolo E, Giannini L, Taddei S, et al
    [OP.7B.10] EFFECT OF BARIATRIC SURGERY ON VASCULAR AND RENAL BIOMARKERS IN MORBIDLY OBESE, NORMOTENSIVE, NON-DIABETIC PATIENTS.
    J Hypertens. 2016;34 Suppl 2:e88-9.
    PubMed     Text format     Abstract available


  29. KONOSHITA T, Sakai A, Kaeriyama S, Urabe M, et al
    [OP.6D.04] ASSOCIATION STUDY OF ANGIOTENSINASE A (ENPEP) GENOTYPE WITH DIABETIC NEPHROPATHY.
    J Hypertens. 2016;34 Suppl 2:e75-6.
    PubMed     Text format     Abstract available


  30. DIPLA K, Kintiraki E, Grigoriadou I, Triantafyllou G, et al
    [OP.5D.05] IMPAIRED SKELETAL MUSCLE OXYGENATION AND ENDOTHELIAL FUNCTION IN WOMEN WITH GESTATIONAL DIABETES MELLITUS ASSESSED BY NEAR- INFRARED SPECTROSCOPY.
    J Hypertens. 2016;34 Suppl 2:e64.
    PubMed     Text format     Abstract available


  31. DEROSA G, Romano D, D'Angelo A, Maffioli P, et al
    [OP.4C.09] COMPARISON BETWEEN CANRENONE OR HYDROCHLOROTHIAZIDE IN ADDITION TO SARTANS IN HYPERTENSIVE DIABETIC PATIENTS.
    J Hypertens. 2016;34 Suppl 2:e49.
    PubMed     Text format     Abstract available


  32. FAUVEL J, Joly D, Choukroun G, Dussol B, et al
    [OP.LB01.09] PREDICTION OF CV EVENT IN DIABETIC NEPHROPATHY.
    J Hypertens. 2016;34 Suppl 2:e38.
    PubMed     Text format     Abstract available


  33. CURRIE G, Flynn J, Lindhardt M, Mischak H, et al
    [OP.1D.10] THE CKD273 URINARY PROTEOMIC CLASSIFIER IS NOT A MARKER OF GENERALISED VASCULAR DISEASE IN TYPE 2 DIABETIC PATIENTS WITH NORMAL RENAL FUNCTION.
    J Hypertens. 2016;34 Suppl 2:e14.
    PubMed     Text format     Abstract available


  34. DALIRY A, Rangel Silvares R, N G da Silva Pereira E, E Ilaquita Flores E, et al
    [OP.1D.09] LIVER DAMAGE DUE TO DIABETES INVOLVES MULTIPLE PATHWAYS AND INDUCES MICROCIRCULATION ALTERATIONS: THE EFFECT OF METFORMIN PLUS INSULIN TREATMENT.
    J Hypertens. 2016;34 Suppl 2:e14.
    PubMed     Text format     Abstract available


  35. LE H, Marchant I, Boissel JP, Nony P, et al
    [OP.1D.08] SYNERGETIC PREVENTION OF SUDDEN DEATH BY ACEI, STATIN AND GLIFLOZIN IN TYPE 2 DIABETES: A SIMULATION STUDY.
    J Hypertens. 2016;34 Suppl 2:e13-4.
    PubMed     Text format     Abstract available


  36. JUMAR A, Ott C, Kistner I, Friedrich S, et al
    [OP.1D.07] EARLY SIGNS OF END-ORGAN DAMAGE IN RETINAL ARTERIOLES IN TYPE 2 DIABETIC IN COMPARISON WITH HYPERTENSIVE PATIENTS.
    J Hypertens. 2016;34 Suppl 2:e13.
    PubMed     Text format     Abstract available


  37. VEUGEN M, Henry R, van Sloten T, Hermeling E, et al
    [OP.1D.05] TYPE 2 DIABETES IS ASSOCIATED WITH GREATER CAROTID STIFFNESS AND GREATER PRESSURE-DEPENDENCY OF CAROTID STIFFNESS -THE MAASTRICHT STUDY.
    J Hypertens. 2016;34 Suppl 2:e13.
    PubMed     Text format     Abstract available


  38. KIM S, Kim JS, Lim SY, Shin C, et al
    [OP.1D.04] SUBCLINICAL LEFT VENTRICULAR DIASTOLIC DYSFUNCTION AND INCIDENT TYPE 2 DIABETES MELLITUS: A COMMUNITY-BASED COHORT STUDY.
    J Hypertens. 2016;34 Suppl 2:e12-3.
    PubMed     Text format     Abstract available


  39. POLONIA J, Ferreira C, Castro P, Penas S, et al
    [OP.1D.03] NIGHTTIME BLOOD PRESSURE IS THE MAJOR DETERMINANT FACTOR OF BOTH MACROVASCULAR AND MICROVASCULAR LESIONS IN A COOHORT OF TYPE 2 DIABETIC AND NON-DIABETIC HYPERTENSIVE PATIENTS.
    J Hypertens. 2016;34 Suppl 2:e12.
    PubMed     Text format     Abstract available


  40. NIBOUCHE N, Lanasri N, Chibane A, Zeraoulia F, et al
    [OP.1D.02] ORTHOSTATIC HYPERTENSION IN NORMOTENSIVE PATIENTS PREDICTS PERMANENT ARTERIAL HYPERTENSION IN TYPE 2 DIABETES MELLITUS.
    J Hypertens. 2016;34 Suppl 2:e12.
    PubMed     Text format     Abstract available


  41. WIJKMAN M, Lanne T, Ostgren CJ, Nystrom FH, et al
    [OP.1D.01] DIASTOLIC ORTHOSTATIC HYPERTENSION PREDICTS A FAVORABLE CARDIOVASCULAR PROGNOSIS IN TYPE 2 DIABETES.
    J Hypertens. 2016;34 Suppl 2:e12.
    PubMed     Text format     Abstract available


  42. FACONTI L, Mills CE, Morant S, Gu H, et al
    [OP.LB03.06] EFFECTS OF SPIRONOLACTONE AND INORGANIC NITRATE AS BEETROOT JUICE ON CARDIAC STRUCTURE AND PERFORMANCE IN PATIENTS AT RISK OF OR WITH TYPE 2 DIABETES: THE VASERA TRIAL.
    J Hypertens. 2016;34 Suppl 2:e112-3.
    PubMed     Text format     Abstract available


  43. AGNOLETTI D, Lieber A, Valbusa F, Arcaro G, et al
    [OP.LB03.03] THE RELATIONSHIP BETWEEN DIASTOLIC FUNCTION AND CENTRAL HEMODYNAMICS IN DIABETIC HYPERTENSIVE PATIENTS.
    J Hypertens. 2016;34 Suppl 2:e111-2.
    PubMed     Text format     Abstract available


  44. BURKO N, Salyamova L, Matrosova I, Oleynikov V, et al
    [OP.8B.03] EFFECT OF CPAP THERAPY ON CENTRAL PRESSURE AND RIGIDITY IN PATIENTS WITH TYPE 2 DIABETES.
    J Hypertens. 2016;34 Suppl 2:e100.
    PubMed     Text format     Abstract available


  45. YANNOUTSOS A, Ahouah M, Dreyfuss Tubiana C, Topouchian J, et al
    [OP.1C.08] HEMODYNAMIC PARAMETERS IN HYPERTENSIVE DIABETIC PATIENTS.
    J Hypertens. 2016;34 Suppl 2:e10.
    PubMed     Text format     Abstract available


  46. LIU Z, Zhao Y, Dong Y, Lu B, et al
    OS 10-02 EFFECTS OF HELICOBACTER PYLORI INFECTION ON ATHEROSCLEROSIS WITH HYPERTENSION AND TYPE 2 DIABETES MELLITUS IN AGED POPULATION.
    J Hypertens. 2016;34 Suppl 1:e72.
    PubMed     Text format     Abstract available


  47. WEI-TING C, Zhih-Cherng C, Juei-Tang C
    OS 05-08 ELMISARTAN IMPROVES CARDIAC FIBROSIS IN DIABETES THROUGH PPARdelta/STAT3 PATHWAY-FROM BEDSIDE TO BENCH.
    J Hypertens. 2016;34 Suppl 1:e60.
    PubMed     Text format     Abstract available


  48. ABASSI Z, Leor J, Landa N, Younis F, et al
    OS 05-04 EMPAGLIFLOZIN EXERTS CARDIO- AND NEPHRO-PROTECTIVE EFFECTS IN COHEN-ROSENTHAL DIABETIC HYPERTENSIVE RATS.
    J Hypertens. 2016;34 Suppl 1:e58-9.
    PubMed     Text format     Abstract available


  49. ZHU Z
    BR 08-1 HIGH SODIUM INTAKE REDUCTION IN DIABETES WITH HYPERTENSION.
    J Hypertens. 2016;34 Suppl 1:e544.
    PubMed     Text format     Abstract available


  50. SUNG KC
    OS 01-06 LOW GRADE ALBUMINURIA IS A PREDICTOR OF INCIDENT HYPERTENSION AND CARDIOVASCULAR MORTALITY BUT IS NOT A PREDICTOR OF INCIDENT TYPE 2 DIABETES.
    J Hypertens. 2016;34 Suppl 1:e45-6.
    PubMed     Text format     Abstract available


  51. LEE JY, Sung KC
    OS 37-03 IMPACT OF CHANGE IN EXERCISE DOSE ON RISK OF NEWLY DEVELOPED HYPERTENSION AND DIABETES MELLITUS IN KOREAN MEN.
    J Hypertens. 2016;34 Suppl 1:e405-6.
    PubMed     Text format     Abstract available


  52. MURAOKA H, Hasegawa K, Wakino S
    OS 36-03 E-BOX CpG HYPOMETHYLATION OF NMN-PRODUCING ENZYME NAMPT IN PROXIMAL TUBULES ENABLES CONSTANT SUPPLY OF NMN FROM TUBULES TO GLOMERULI, WHICH IS DISRUPTED IN DIABETIC NEPHROPATHY.
    J Hypertens. 2016;34 Suppl 1:e402.
    PubMed     Text format     Abstract available


  53. WONG R, Nealon R, Raederstorff D, Howe P, et al
    OS 34-02 CONCENTRATION DEPENDENT EFFECT OF PLASMA RESVERATROL ON CEREBRAL VASODILATOR RESPONSIVENESS (CVR) IN ADULTS WITH TYPE-2 DIABETES MELLITUS (T2DM).
    J Hypertens. 2016;34 Suppl 1:e396.
    PubMed     Text format     Abstract available


  54. RYUNO H, Kamide K, Gondo Y, Kabayama M, et al
    OS 34-01 ASSOCIATION OF COMBINATION OF HYPERTENSION AND DIABETES WITH COGNITIVE FUNCTION AMONG THE 70-YEARS-OLD JAPANESE GENERAL POPULATION FROM LONGITUDINAL OBSERVATION IN THE SONIC STUDY.
    J Hypertens. 2016;34 Suppl 1:e396.
    PubMed     Text format     Abstract available


  55. TANAKA M, Nishimura T, Sekioka R, Kawai T, et al
    OS 33-07 LOW SERUM ALBUMIN CONCENTRATION IN HYPERTENSIVE PATIENTS COMPLICATED BY TYPE 2 DIABETES IS ASSOCIATED WITH MICROVASCULAR COMPLICATIONS.
    J Hypertens. 2016;34 Suppl 1:e394-5.
    PubMed     Text format     Abstract available


  56. OGOLA E
    OS 33-05 HIGH PREVALENCE AND POOR CONTROL OF HYPERTENSION AND ASSOCIATED CARDIOVASCULAR RISK FACORS IN DIABETIC PATIENTS IN A RURAL HOSPITAL IN KENYA.
    J Hypertens. 2016;34 Suppl 1:e394.
    PubMed     Text format     Abstract available


  57. LIU M, Li L, Chu J, Dai G, et al
    OS 33-03 SERUM N1-METHYLNICOTINAMIDE IS ASSOCIATED WITH OBESITY AND DIABETES IN CHINESE.
    J Hypertens. 2016;34 Suppl 1:e393-4.
    PubMed     Text format     Abstract available


  58. SEUNG-WOON R, Geol CB, Hu L, Oh NJ, et al
    OS 31-04 COMPARISON OF CALCIUM CHANNEL BLOCKERS VERSUS CALCIUM CHANNEL BLOCKERS WITH RENIN ANGIOTENSIN SYSTEM BLOCKERS ON THE DEVELOPMENT OF NEW-ONSET DIABETES MELLITUS IN HYPERTENSIVE PATIENTS.
    J Hypertens. 2016;34 Suppl 1:e388-9.
    PubMed     Text format     Abstract available


  59. KIM-MITSUYAMA S
    SY 12-3 ARE RAS INHIBITORS NECESSARY FOR ALL PATIENTS WITH DIABETES AND CHRONIC KIDNEY DISEASE?
    J Hypertens. 2016;34 Suppl 1:e367.
    PubMed     Text format     Abstract available


  60. LEE HY, Park CS, Na SH, Kim KJ, et al
    ISH AHA-2 A CASE OF CHRONIC INDOLENT PHEOCHROMOCYTOMA WHICH CAUSED MEDICALLY-CONTROLLED HYPERTENSION BUT TREATMENT-RESISTANT DIABETES MELLITUS.
    J Hypertens. 2016;34 Suppl 1:e35.
    PubMed     Text format     Abstract available


  61. KARIO K
    DB 01-3 TREATMENT TARGET OF SYSTOLIC BLOOD PRESSURE IN DIABETES MAY DIFFER ACCORDING TO ETHNICITY (PRO).
    J Hypertens. 2016;34 Suppl 1:e26.
    PubMed     Text format     Abstract available


  62. CHAN J, Lo CS, Shi Y, Chenier I, et al
    OS 25-03 OVEREXPRESSION OF HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN F PREVENTS SYSTEMIC HYPERTENSION AND KIDNEY INJURY AND NORMALIZES RENAL RENIN-ANGIOTENSIN SYSTEM GENES EXPRESSION IN TYPE 2 DIABETIC DB/DB TRANSGENIC MICE.
    J Hypertens. 2016;34 Suppl 1:e245.
    PubMed     Text format     Abstract available


  63. LEE JW, Lim NK, Lee JH, Park HY, et al
    OS 22-03 Joint effect of pre-existing hypertension and diabetes on cardiovascular diseases and mortality in the middle-aged Koreans.
    J Hypertens. 2016;34 Suppl 1:e238-9.
    PubMed     Text format     Abstract available


  64. PARADIS P, Ouerd S, Idris-Khodja N, Trindade M, et al
    OS 21-01 NOX1 OR NOX4 DELETION PREVENTS TYPE 1 DIABETES-INDUCED ENDOTHELIAL DYSFUNCTION.
    J Hypertens. 2016;34 Suppl 1:e235.
    PubMed     Text format     Abstract available


  65. IMAIZUMI Y, Eguchi K, Kaihara T, Urano K, et al
    OS 18-05 SARCOPENIA IS INDEPENDENTLY ASSOCIATED WITH ARTERIAL STIFFNESS IN PATIENTS WITH TYPE 2 DIABETES.
    J Hypertens. 2016;34 Suppl 1:e225.
    PubMed     Text format     Abstract available


  66. EGUCHI K
    SY 07-3 WHICH BP LEVELS ARE ADEQUATE TARGETS FOR THE MANAGEMENT OF DIABETIC HYPERTENSIVE PATIENTS IN ASIA?
    J Hypertens. 2016;34 Suppl 1:e21.
    PubMed     Text format     Abstract available


  67. MESSERLI F
    SY 07-2 SHOULD DIABETES MELLITUS REMAIN A COMPELLING INDICATION FOR USE OF RENIN ANGIOTENSIN SYSTEM BLOCKERS?
    J Hypertens. 2016;34 Suppl 1:e21.
    PubMed     Text format     Abstract available


  68. SIMON P, Krajcoviechova A, Harvey F, Haloui M, et al
    YIA 03-01 VALIDATION OF GENETIC DETERMINANTS OF UNMET NEEDS IN THE TREATMENT OF KIDNEY DISEASE IN TYPE-2 DIABETES.
    J Hypertens. 2016;34 Suppl 1:e204.
    PubMed     Text format     Abstract available


  69. HEAGERTY A
    SY 06-1 OBESITY, DIABETES AND HYPERTENSION: ARE ADIPOKINES RESPONSIBLE?
    J Hypertens. 2016;34 Suppl 1:e20.
    PubMed     Text format     Abstract available


  70. GRASSI G
    ME 02-3 EXTENDING SPRINT RESULTS TO DIABETICS.
    J Hypertens. 2016;34 Suppl 1:e197.
    PubMed     Text format     Abstract available


  71. APPEL L
    DB 02-3 STRICT CONTROL OF HYPERTENSION IN THE ELDERLY WITH DIABETES AND CHRONIC KIDNEY DISEASE (PRO).
    J Hypertens. 2016;34 Suppl 1:e190.
    PubMed     Text format     Abstract available


  72. SHIMAMOTO K
    SY 01-3 HOW DO WE RECONCILE THE DISCREPANCY OF BLOOD PRESSURE GUIDELINES FOR PATIENTS WITH OLD AGE, DIABETES AND CKD?
    J Hypertens. 2016;34 Suppl 1:e12.
    PubMed     Text format     Abstract available


  73. ZHU Z
    BR 08-1 HIGH SODIUM INTAKE REDUCTION IN DIABETES WITH HYPERTENSION.
    J Hypertens. 2016;34 Suppl 1 - ISH 2016 Abstract Book:e544.
    PubMed     Text format     Abstract available


  74. LEE JY, Sung KC
    OS 37-03 IMPACT OF CHANGE IN EXERCISE DOSE ON RISK OF NEWLY DEVELOPED HYPERTENSION AND DIABETES MELLITUS IN KOREAN MEN.
    J Hypertens. 2016;34 Suppl 1 - ISH 2016 Abstract Book:e405-e406.
    PubMed     Text format     Abstract available


  75. MURAOKA H, Hasegawa K, Wakino S
    OS 36-03 E-BOX CpG HYPOMETHYLATION OF NMN-PRODUCING ENZYME NAMPT IN PROXIMAL TUBULES ENABLES CONSTANT SUPPLY OF NMN FROM TUBULES TO GLOMERULI, WHICH IS DISRUPTED IN DIABETIC NEPHROPATHY.
    J Hypertens. 2016;34 Suppl 1 - ISH 2016 Abstract Book:e402.
    PubMed     Text format     Abstract available


  76. WONG R, Nealon R, Raederstorff D, Howe P, et al
    OS 34-02 CONCENTRATION DEPENDENT EFFECT OF PLASMA RESVERATROL ON CEREBRAL VASODILATOR RESPONSIVENESS (CVR) IN ADULTS WITH TYPE-2 DIABETES MELLITUS (T2DM).
    J Hypertens. 2016;34 Suppl 1 - ISH 2016 Abstract Book:e396.
    PubMed     Text format     Abstract available


  77. RYUNO H, Kamide K, Gondo Y, Kabayama M, et al
    OS 34-01 ASSOCIATION OF COMBINATION OF HYPERTENSION AND DIABETES WITH COGNITIVE FUNCTION AMONG THE 70-YEARS-OLD JAPANESE GENERAL POPULATION FROM LONGITUDINAL OBSERVATION IN THE SONIC STUDY.
    J Hypertens. 2016;34 Suppl 1 - ISH 2016 Abstract Book:e396.
    PubMed     Text format     Abstract available


  78. TANAKA M, Nishimura T, Sekioka R, Kawai T, et al
    OS 33-07 LOW SERUM ALBUMIN CONCENTRATION IN HYPERTENSIVE PATIENTS COMPLICATED BY TYPE 2 DIABETES IS ASSOCIATED WITH MICROVASCULAR COMPLICATIONS.
    J Hypertens. 2016;34 Suppl 1 - ISH 2016 Abstract Book:e394-e395.
    PubMed     Text format     Abstract available


  79. OGOLA E
    OS 33-05 HIGH PREVALENCE AND POOR CONTROL OF HYPERTENSION AND ASSOCIATED CARDIOVASCULAR RISK FACORS IN DIABETIC PATIENTS IN A RURAL HOSPITAL IN KENYA.
    J Hypertens. 2016;34 Suppl 1 - ISH 2016 Abstract Book:e394.
    PubMed     Text format     Abstract available


  80. LIU M, Li L, Chu J, Dai G, et al
    OS 33-03 SERUM N1-METHYLNICOTINAMIDE IS ASSOCIATED WITH OBESITY AND DIABETES IN CHINESE.
    J Hypertens. 2016;34 Suppl 1 - ISH 2016 Abstract Book:e393-e394.
    PubMed     Text format     Abstract available


  81. SEUNG-WOON R, Geol CB, Hu L, Oh NJ, et al
    OS 31-04 COMPARISON OF CALCIUM CHANNEL BLOCKERS VERSUS CALCIUM CHANNEL BLOCKERS WITH RENIN ANGIOTENSIN SYSTEM BLOCKERS ON THE DEVELOPMENT OF NEW-ONSET DIABETES MELLITUS IN HYPERTENSIVE PATIENTS.
    J Hypertens. 2016;34 Suppl 1 - ISH 2016 Abstract Book:e388-e389.
    PubMed     Text format     Abstract available


  82. KIM-MITSUYAMA S
    SY 12-3 ARE RAS INHIBITORS NECESSARY FOR ALL PATIENTS WITH DIABETES AND CHRONIC KIDNEY DISEASE?
    J Hypertens. 2016;34 Suppl 1 - ISH 2016 Abstract Book:e367.
    PubMed     Text format     Abstract available


  83. CHAN J, Lo CS, Shi Y, Chenier I, et al
    OS 25-03 OVEREXPRESSION OF HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN F PREVENTS SYSTEMIC HYPERTENSION AND KIDNEY INJURY AND NORMALIZES RENAL RENIN-ANGIOTENSIN SYSTEM GENES EXPRESSION IN TYPE 2 DIABETIC DB/DB TRANSGENIC MICE.
    J Hypertens. 2016;34 Suppl 1 - ISH 2016 Abstract Book:e245.
    PubMed     Text format     Abstract available


  84. LEE JW, Lim NK, Lee JH, Park HY, et al
    OS 22-03 Joint effect of pre-existing hypertension and diabetes on cardiovascular diseases and mortality in the middle-aged Koreans.
    J Hypertens. 2016;34 Suppl 1 - ISH 2016 Abstract Book:e238-e239.
    PubMed     Text format     Abstract available


  85. PARADIS P, Ouerd S, Idris-Khodja N, Trindade M, et al
    OS 21-01 NOX1 OR NOX4 DELETION PREVENTS TYPE 1 DIABETES-INDUCED ENDOTHELIAL DYSFUNCTION.
    J Hypertens. 2016;34 Suppl 1 - ISH 2016 Abstract Book:e235.
    PubMed     Text format     Abstract available


  86. IMAIZUMI Y, Eguchi K, Kaihara T, Urano K, et al
    OS 18-05 SARCOPENIA IS INDEPENDENTLY ASSOCIATED WITH ARTERIAL STIFFNESS IN PATIENTS WITH TYPE 2 DIABETES.
    J Hypertens. 2016;34 Suppl 1 - ISH 2016 Abstract Book:e225.
    PubMed     Text format     Abstract available


  87. SIMON P, Krajcoviechova A, Harvey F, Haloui M, et al
    YIA 03-01 VALIDATION OF GENETIC DETERMINANTS OF UNMET NEEDS IN THE TREATMENT OF KIDNEY DISEASE IN TYPE-2 DIABETES.
    J Hypertens. 2016;34 Suppl 1 - ISH 2016 Abstract Book:e204.
    PubMed     Text format     Abstract available


  88. GRASSI G
    ME 02-3 EXTENDING SPRINT RESULTS TO DIABETICS.
    J Hypertens. 2016;34 Suppl 1 - ISH 2016 Abstract Book:e197.
    PubMed     Text format     Abstract available


  89. APPEL L
    DB 02-3 STRICT CONTROL OF HYPERTENSION IN THE ELDERLY WITH DIABETES AND CHRONIC KIDNEY DISEASE (PRO).
    J Hypertens. 2016;34 Suppl 1 - ISH 2016 Abstract Book:e190.
    PubMed     Text format     Abstract available


  90. LIU Z, Zhao Y, Dong Y, Lu B, et al
    OS 10-02 EFFECTS OF HELICOBACTER PYLORI INFECTION ON ATHEROSCLEROSIS WITH HYPERTENSION AND TYPE 2 DIABETES MELLITUS IN AGED POPULATION.
    J Hypertens. 2016;34 Suppl 1 - ISH 2016 Abstract Book:e72.
    PubMed     Text format     Abstract available


  91. WEI-TING C, Zhih-Cherng C, Juei-Tang C
    OS 05-08 ELMISARTAN IMPROVES CARDIAC FIBROSIS IN DIABETES THROUGH PPARdelta/STAT3 PATHWAY-FROM BEDSIDE TO BENCH.
    J Hypertens. 2016;34 Suppl 1 - ISH 2016 Abstract Book:e60.
    PubMed     Text format     Abstract available


  92. ABASSI Z, Leor J, Landa N, Younis F, et al
    OS 05-04 EMPAGLIFLOZIN EXERTS CARDIO- AND NEPHRO-PROTECTIVE EFFECTS IN COHEN-ROSENTHAL DIABETIC HYPERTENSIVE RATS.
    J Hypertens. 2016;34 Suppl 1 - ISH 2016 Abstract Book:e58-e59.
    PubMed     Text format     Abstract available


  93. SUNG KC
    OS 01-06 LOW GRADE ALBUMINURIA IS A PREDICTOR OF INCIDENT HYPERTENSION AND CARDIOVASCULAR MORTALITY BUT IS NOT A PREDICTOR OF INCIDENT TYPE 2 DIABETES.
    J Hypertens. 2016;34 Suppl 1 - ISH 2016 Abstract Book:e45-e46.
    PubMed     Text format     Abstract available


  94. LEE HY, Park CS, Na SH, Kim KJ, et al
    ISH AHA-2 A CASE OF CHRONIC INDOLENT PHEOCHROMOCYTOMA WHICH CAUSED MEDICALLY-CONTROLLED HYPERTENSION BUT TREATMENT-RESISTANT DIABETES MELLITUS.
    J Hypertens. 2016;34 Suppl 1 - ISH 2016 Abstract Book:e35.
    PubMed     Text format     Abstract available


  95. KARIO K
    DB 01-3 TREATMENT TARGET OF SYSTOLIC BLOOD PRESSURE IN DIABETES MAY DIFFER ACCORDING TO ETHNICITY (PRO).
    J Hypertens. 2016;34 Suppl 1 - ISH 2016 Abstract Book:e26.
    PubMed     Text format     Abstract available


  96. EGUCHI K
    SY 07-3 WHICH BP LEVELS ARE ADEQUATE TARGETS FOR THE MANAGEMENT OF DIABETIC HYPERTENSIVE PATIENTS IN ASIA?
    J Hypertens. 2016;34 Suppl 1 - ISH 2016 Abstract Book:e21.
    PubMed     Text format     Abstract available


  97. MESSERLI F
    SY 07-2 SHOULD DIABETES MELLITUS REMAIN A COMPELLING INDICATION FOR USE OF RENIN ANGIOTENSIN SYSTEM BLOCKERS?
    J Hypertens. 2016;34 Suppl 1 - ISH 2016 Abstract Book:e21.
    PubMed     Text format     Abstract available


  98. HEAGERTY A
    SY 06-1 OBESITY, DIABETES AND HYPERTENSION: ARE ADIPOKINES RESPONSIBLE?
    J Hypertens. 2016;34 Suppl 1 - ISH 2016 Abstract Book:e20.
    PubMed     Text format     Abstract available


  99. SHIMAMOTO K
    SY 01-3 HOW DO WE RECONCILE THE DISCREPANCY OF BLOOD PRESSURE GUIDELINES FOR PATIENTS WITH OLD AGE, DIABETES AND CKD?
    J Hypertens. 2016;34 Suppl 1 - ISH 2016 Abstract Book:e12.
    PubMed     Text format     Abstract available


    August 2016
  100. MUSICHA C, Crampin AC, Kayuni N, Koole O, et al
    Accessing clinical services and retention in care following screening for hypertension and diabetes among Malawian adults: an urban/rural comparison.
    J Hypertens. 2016.
    PubMed     Text format     Abstract available


  101. DEMPSEY PC, Sacre JW, Larsen RN, Straznicky NE, et al
    Interrupting prolonged sitting with brief bouts of light walking or simple resistance activities reduces resting blood pressure and plasma noradrenaline in type 2 diabetes.
    J Hypertens. 2016.
    PubMed     Text format     Abstract available


  102. CHAPPELL MC
    Amiloride and the diabetic kidney.
    J Hypertens. 2016;34:1500-1.
    PubMed     Text format    


    July 2016
  103. DE COSMO S, Viazzi F, Piscitelli P, Giorda C, et al
    Blood pressure status and the incidence of diabetic kidney disease in patients with hypertension and type 2 diabetes.
    J Hypertens. 2016.
    PubMed     Text format     Abstract available


  104. CLOTET S, Soler MJ, Rebull M, Gimeno J, et al
    Gonadectomy prevents the increase in blood pressure and glomerular injury in angiotensin-converting enzyme 2 knockout diabetic male mice. Effects on renin-angiotensin system.
    J Hypertens. 2016.
    PubMed     Text format     Abstract available


    June 2016
  105. SONG J, Sheng CS, Huang QF, Li LH, et al
    Management of hypertension and diabetes mellitus by cardiovascular and endocrine physicians: a China registry.
    J Hypertens. 2016.
    PubMed     Text format     Abstract available


    May 2016
  106. ANDERSEN H, Hansen PB, Bistrup C, Nielsen F, et al
    Significant natriuretic and antihypertensive action of the epithelial sodium channel blocker amiloride in diabetic patients with and without nephropathy.
    J Hypertens. 2016.
    PubMed     Text format     Abstract available


    February 2016
  107. GRIFFIN TP, Browne GA, Wall D, Dennedy MC, et al
    A cross-sectional study of the effects of beta-blocker therapy on the interpretation of the aldosterone/renin ratio: can dosing regimen predict effect?
    J Hypertens. 2016;34:307-15.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: